Abstract
Aims
To evaluate the structured PROSIT® disease management programme for high-risk diabetic patients in primary care with respect to the cardio-vascular risk profile and mortality.
Subjects and Methods
Retrospectively 55 albuminuric Type 2 diabetic patients included into the PROSIT® programme from 1994 to 1999 (intervention group: age 66.6 ± 10.5 years, known duration of diabetes 8.9 ± 6.5 years) were compared with 58 albuminuric patients not participating in the PROSIT® programme (control group: age 68.5 ± 10.4 years, known duration of diabetes 8.5 ± 6.7 years). Within PROSIT® a structured multifactorial intervention programme was applied. The main characteristics of this intervention were strict follow-ups of the patient's risk profile every three months and the use of quality management methods (definition of target values, structured documentation, central data feedback with diagnostic and therapeutic recommendations based on European guidelines). The cardio-vascular risk profile, therapeutic intervention, and secondary diabetic complications were compared between both groups in 1994 and 1999.
Results
In the period from 1994 to 1999 the intervention group showed a significant improvement in the vascular risk profile, while the control group did not. In 1999 the mean arterial blood pressure was significantly lower compared to the control group (115 ± 13 mm Hg vs. 125 ± 16 mm Hg, p < 0.05). The HbA1c improved only in the intervention group and in 1999 it was significantly lower than in the control group (7.0 ± 1.3 % vs. 8.4 ± 1.8 %, p < 0.01). Moreover, the occurrence of clinical endpoints in the intervention group could be reduced: Both the mortalitly rate (14.5 % vs. 34.5 %, p < 0.05) and the rate of new myocardial infarctions (6 % vs. 20 %, p < 0.05) of the intervention group were significantly lower.
Conclusions
Participation of albuminuric Type 2 diabetic patients and their physicians in a structured intervention programme showed positive effects on the cardio-vascular risk profile and endpoints compared with a group of non-participating patients and physicians.
Key words
Type 2 diabetes mellitus - diabetic nephropathy - intervention - disease management - quality management
References
1
Amos A F, McCarty D J, Zimmet P.
The rising global burden of diabetes and its complications: estimates and projections to the year 2010.
Diabet Med.
1997;
14 (Suppl 5)
S1-85
2
Borch-Johnsen K, Wenzel H, Viberti G C, Mogensen C E.
Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? (published erratum appears in BMJ 1993; 28: 307: 543) [see comments].
BMJ.
1993;
306
1722-1725
3
DCCT .
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [see comments].
N Engl J Med.
1993;
329
977-986
4
Deckert T, Yokoyama H, Mathiesen E, Ronn B, Jensen T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen J S.
Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes.
BMJ.
1996;
312
871-874
5
Detournay B, Fagnani F, Pribil C, Eschwege E.
Medical resources consumption of type 2 diabetics in France in 1998.
Diabetes Metab.
2000;
26
225-231
6
Gaede P, Vedel P, Parving H H, Pedersen O.
Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study [see comments].
Lancet.
1999;
353
617-622
37
Gaede P, Vedel P, Larsen N, Jensen G VH, Parving H H, Pedersen O.
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
N Engl J Med.
2003;
348
383-393
7
Garg A.
Dyslipoproteinemia and diabetes.
Endocrinol Metab Clin North Am.
1998;
27
613-615
8
Grimshaw J, Russel I.
Achieving health gain through clinical guidelines: II: Ensuring guidelines change medical practice.
Quality in Health Care.
1994;
3
45-52
9
Hansson L, Zanchetti A, Carruthers S G, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn K H, Wedel H, Westerling S.
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group [see comments].
Lancet.
1998;
351
1755-1762
10
Hasslacher C.
Clinical significance of microalbuminuria and evaluation of the Micral-Test.
Clin Biochem.
1993;
26
283-287
11
Jager A, Kostense P J, Ruhe H G, Heine R J, Nijpels G, Dekker J M, Bouter L M, Stehouwer C D.
Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study.
Arterioscler Thromb Vasc Biol.
1999;
19
617-624
12
Jonsson B.
The economic impact of diabetes.
Diabetes Care.
1998;
21 (Suppl 3)
C7-10
13
Kreisberg R A.
Diabetic dyslipidemia.
Am J Cardiol.
1998;
82
67U-73U
14
Laakso M, Lehto S, Penttila I, Pyorala K.
Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes [see comments].
Circulation.
1993;
88
1421-1430
15
Laakso M.
Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus. The Finnish studies.
Ann Intern Med.
1996;
124
127-130
16
Lippert J, Ritz E, Schwarzbeck A, Schneider P.
The rising tide of endstage renal failure from diabetic nephropathy type II - an epidemiological analysis [see comments].
Nephrol Dial Transplant.
1995;
10
462-467
17
Luno J, Garcia de Vinuesa S, Gomez-Campdera F, Lorenzo I, Valderrabano F.
Effects of antihypertensive therapy on progression of diabetic nephropathy.
Kidney Int Suppl.
1998;
68
S112-119
18
Mathiesen E R, Ronn B, Storm B, Foght H, Deckert T.
The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study.
Diabet Med.
1995;
12
482-487
19
Mogensen C E.
Management of early nephropathy in diabetic patients.
Ann Rev Med.
1995;
46
79-93
20
Mogensen C E, Viberti G C, Peheim E, Kutter D, Hasslacher C, Hofmann W, Renner R, Bojestig M, Poulsen P L, Scott G, Thoma J, Kuefer J, Nilsson B, Gambke B, Mueller P, Steinbiss J, Willamowski K D.
Multicenter evaluation of the Micral-Test II test strip, an immunologic rapid test for the detection of microalbuminuria [see comments].
Diabetes Care.
1997;
20
1642-1646
21
Mogensen C E.
Natural history of cardiovascular and renal disease in patients with type 2 diabetes: effect of therapeutic interventions and risk modification.
Am J Cardiol.
1998;
82
4R-8R
22
Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M.
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study [see comments].
Diabetes Res Clin Pract.
1995;
28
103-117
23
Piehlmeier W, Renner R, Schramm W, Kimmerling T, Garbe S, Proetzsch R, Fahn J, Piwernetz K, Landgraf R.
Screening of diabetic patients for microalbuminuria in primary care- The PROSIT-Project. Proteinuria Screening and Intervention.
Exp Clin Endocrinol Diabetes.
1999;
107
244-251
24
Piehlmeier W, Renner R, Kimmerling T, Schramm W, Garbe S, Proetzsch R, Fahn J, Piwernetz K, Landgraf R.
Evaluation of the Micral-Test S, a Qualitative Immunologic Patient Self-test for Microalbuminuria: the PROSIT Project.
Diabetic Medicine.
1998;
15
883-885
25
Poulsen P L, Ebbehoj E, Hansen K W, Mogensen C E.
Effects of smoking on 24-h ambulatory blood pressure and autonomic function in normoalbuminuric insulin-dependent diabetes mellitus patients.
Am J Hypertens.
1998;
11
1093-1099
26
Ritz E, Lippert J, Keller C.
A rapid rise in the number of type-2 diabetics in kidney failure. Not just a problem of nephrologists (editorial).
Dtsch Med Wochenschr.
1996;
121
1247
27
Ritz E, Rychl, Locatelli F, Halimi S.
End-Stage Renal Failure in Type 2 Diabetes: A Medical Catastrophe of Worldwide Dimensions.
Am J Kidney Dis.
1999;
34
795-808
28
Rychlik I, Miltenberger-Miltenyi G, Ritz E.
The drama of the continuous increase in end-stage renal failure in patients with type II diabetes mellitus.
Nephrol Dial Transplant.
1998;
13 (Suppl 8)
6-10
29
Cooperative Research Group S HEP.
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group [see comments].
JAMA.
1991;
265
3255-3264
30
Sheth J J.
Diabetes, microalbuminuria and hypertension.
Clin Exp Hypertens.
1999;
21
61-68
31
Shichiri M, Kishikawa H, Ohkubo Y, Wake N.
Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.
Diabetes Care.
2000;
23 (Suppl 2)
B21-29
32
Tatti P, Pahor M, Byington R P, Di Mauro P, Guarisco R, Strollo G, Strollo F.
Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM [see comments].
Diabetes Care.
1998;
21
597-603
33
Thivolet C, Ayzac L, Simonet C, Rebattu B, Bernard P, Tourniaire J.
Microalbuminuria and diabetic nephropathy. Detection and correlation with other degenerative complications.
Presse Med.
1990;
19
1075-1080
34
UKPDS-Group.
Intensive blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
BMJ.
1998;
317
703-713
35
UKPDS-Group.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [see comments].
Lancet.
1998 a;
352
837-853
36
UKPDS-Group.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group (published erratum appears in Lancet 1998; 352: 1557) [see comments].
Lancet.
1998 b;
352
854-865
W. Steines
IIIrd Medical Department, Hospital Munich-Bogenhausen
Englschalkinger Str. 77
81925 München
Germany
Phone: + 498992702503
Fax: + 49 89 51 60 21 03
Email: prosit@prosit.de